{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:20:33Z","timestamp":1788193233200,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.virol.2026.111025","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:03:17Z","timestamp":1783494197000},"page":"111025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development of a virus particle fusion assay to study and target virus entry"],"prefix":"10.1016","volume":"623","author":[{"given":"Nicolas","family":"Terzopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Tiplady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.virol.2026.111025_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02275-24","article-title":"Cell binding, uptake, and infection of influenza A virus using recombinant antibody-based receptors","volume":"99","author":"Adu","year":"2025","journal-title":"J. Virol."},{"issue":"40","key":"10.1016\/j.virol.2026.111025_bib2","doi-asserted-by":"crossref","first-page":"16498","DOI":"10.1074\/jbc.M117.791731","article-title":"Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors","volume":"292","author":"Ahn","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.virol.2026.111025_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.virol.2026.111025_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00514-20","article-title":"Differential pressures of SERINC5 and IFITM3 on HIV-1 envelope glycoprotein over the course of HIV-1 infection","volume":"94","author":"Beitari","year":"2020","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.virol.2026.111025_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100152","article-title":"An improved protocol for the production of lentiviral vectors","volume":"1","author":"Brown","year":"2020","journal-title":"STAR Protoc."},{"issue":"5","key":"10.1016\/j.virol.2026.111025_bib6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.4049\/jimmunol.149.5.1779","article-title":"Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion","volume":"149","author":"Burkly","year":"1992","journal-title":"J. Immunol."},{"issue":"22","key":"10.1016\/j.virol.2026.111025_bib7","doi-asserted-by":"crossref","first-page":"13216","DOI":"10.1074\/jbc.270.22.13216","article-title":"Kinetics and thermodynamics of virus binding to receptor. Studies with rhinovirus, intercellular adhesion molecule-1 (ICAM-1), and surface plasmon resonance","volume":"270","author":"Casasnovas","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"7557","key":"10.1016\/j.virol.2026.111025_bib8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.virol.2026.111025_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.883010","article-title":"The expanding arsenal of cytotoxic T cells","volume":"13","author":"Cassioli","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.virol.2026.111025_bib10","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/nbt745","article-title":"A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes","volume":"20","author":"Cavrois","year":"2002","journal-title":"Nat. Biotechnol."},{"issue":"6106","key":"10.1016\/j.virol.2026.111025_bib11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1126\/science.1226359","article-title":"Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy","volume":"338","author":"Chojnacki","year":"2012","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.virol.2026.111025_bib12","article-title":"From design to clinical use: mRNA vaccines for infectious diseases and cancer","volume":"14","author":"Cui","year":"2026","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.virol.2026.111025_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrmicro817","article-title":"Virus entry: molecular mechanisms and biomedical applications","volume":"2","author":"Dimitrov","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"issue":"2","key":"10.1016\/j.virol.2026.111025_bib14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/acschembio.5b00753","article-title":"NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells","volume":"11","author":"Dixon","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"11","key":"10.1016\/j.virol.2026.111025_bib15","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"15","key":"10.1016\/j.virol.2026.111025_bib16","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2026.111025_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-0716-3862-0_6","article-title":"Single-Virion analysis: a method to visualize HIV-1 particle content using Fluorescence Microscopy","volume":"2807","author":"Duchon","year":"2024","journal-title":"Methods Mol. Biol."},{"issue":"10","key":"10.1016\/j.virol.2026.111025_bib18","article-title":"HIV-1 entry mechanisms: Protein-Host receptor interactions and membrane fusion dynamics","volume":"30","author":"Elalouf","year":"2025","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"8","key":"10.1016\/j.virol.2026.111025_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010754","article-title":"Localization and functions of native and eGFP-tagged capsid proteins in HIV-1 particles","volume":"18","author":"Francis","year":"2022","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.virol.2026.111025_bib19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.chom.2018.03.009","article-title":"Single HIV-1 imaging reveals progression of infection through CA-Dependent steps of docking at the nuclear pore, uncoating, and nuclear transport","volume":"23","author":"Francis","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"17","key":"10.1016\/j.virol.2026.111025_bib21","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1073\/pnas.1916054117","article-title":"PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells","volume":"117","author":"Fu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.virol.2026.111025_bib22","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1462-5822.2005.00516.x","article-title":"The ins and outs of HIV replication","volume":"7","author":"Gomez","year":"2005","journal-title":"Cell. Microbiol."},{"issue":"6710","key":"10.1016\/j.virol.2026.111025_bib23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1126\/science.adn5658","article-title":"Structure and inhibition of SARS-CoV-2 spike refolding in membranes","volume":"385","author":"Grunst","year":"2024","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.virol.2026.111025_bib24","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.jmb.2018.03.034","article-title":"Virus entry: looking back and moving forward","volume":"430","author":"Helenius","year":"2018","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.virol.2026.111025_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/v4020258","article-title":"Filovirus entry: a novelty in the viral fusion world","volume":"4","author":"Hunt","year":"2012","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.virol.2026.111025_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7","key":"10.1016\/j.virol.2026.111025_bib27","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ncb1610","article-title":"Filamin-A regulates actin-dependent clustering of HIV receptors","volume":"9","author":"Jim\u00e9nez-Baranda","year":"2007","journal-title":"Nat. Cell Biol."},{"issue":"24","key":"10.1016\/j.virol.2026.111025_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249644","article-title":"Virus-Mediated cell-cell fusion","volume":"21","author":"Leroy","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7989","key":"10.1016\/j.virol.2026.111025_bib29","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/s41586-023-06762-6","article-title":"HIV-1 Env trimers asymmetrically engage CD4 receptors in membranes","volume":"623","author":"Li","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.virol.2026.111025_bib30","article-title":"Virus tracking technologies and their applications in viral life cycle: research advances and future perspectives","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.virol.2026.111025_bib32","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1128\/JVI.01531-10","article-title":"The IFITM proteins inhibit HIV-1 infection","volume":"85","author":"Lu","year":"2011","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.virol.2026.111025_bib31","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/jvi.67.11.6542-6550.1993","article-title":"Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions","volume":"67","author":"Lu","year":"1993","journal-title":"J. Virol."},{"issue":"17","key":"10.1016\/j.virol.2026.111025_bib33","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.jmb.2018.06.024","article-title":"Virus-Receptor interactions: the key to cellular invasion","volume":"430","author":"Maginnis","year":"2018","journal-title":"J. Mol. Biol."},{"issue":"6","key":"10.1016\/j.virol.2026.111025_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41577-021-00626-8","article-title":"Lessons in self-defence: inhibition of virus entry by intrinsic immunity","volume":"22","author":"Majdoul","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.virol.2026.111025_bib35","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/S0021-9258(19)75715-9","article-title":"Characterization of the fusion of enveloped viruses with the plasma membrane of Saccharomyces cerevisiae spheroplasts","volume":"262","author":"Makarow","year":"1987","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.virol.2026.111025_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/adt.2015.639","article-title":"High-Throughput HIV-Cell fusion assay for discovery of virus entry inhibitors","volume":"13","author":"Marin","year":"2015","journal-title":"Assay Drug Dev. Technol."},{"issue":"7","key":"10.1016\/j.virol.2026.111025_bib37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40265-018-0907-5","article-title":"Ibalizumab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.virol.2026.111025_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1083\/jcb.200203150","article-title":"Visualization of the intracellular behavior of HIV in living cells","volume":"159","author":"McDonald","year":"2002","journal-title":"J. Cell Biol."},{"issue":"3","key":"10.1016\/j.virol.2026.111025_bib39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2009.02.046","article-title":"HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes","volume":"137","author":"Miyauchi","year":"2009","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.virol.2026.111025_bib40","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/jvi.66.8.4784-4793.1992","article-title":"A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells","volume":"66","author":"Moore","year":"1992","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.virol.2026.111025_bib41","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41564-019-0392-y","article-title":"Antibody responses to viral infections: a structural perspective across three different enveloped viruses","volume":"4","author":"Murin","year":"2019","journal-title":"Nat. Microbiol."},{"issue":"1","key":"10.1016\/j.virol.2026.111025_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e3182732746","article-title":"Anti-CD4 monoclonal antibody Ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope","volume":"62","author":"Pace","year":"2013","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"12","key":"10.1016\/j.virol.2026.111025_bib43","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1128\/jvi.67.12.7229-7237.1993","article-title":"Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis","volume":"67","author":"Paxton","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2026.111025_bib44","series-title":"Viruses","first-page":"37","article-title":"Chapter 4 - methods to Study viruses","author":"Payne","year":"2017"},{"issue":"8","key":"10.1016\/j.virol.2026.111025_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms13081785","article-title":"Exploring the use of viral vectors pseudotyped with viral glycoproteins as tools to study antibody-mediated neutralizing activity","volume":"13","author":"Ramos-Cela","year":"2025","journal-title":"Microorganisms"},{"issue":"7475","key":"10.1016\/j.virol.2026.111025_bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"Shingai","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.virol.2026.111025_bib47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-981-99-0113-5_4","article-title":"Pseudotyped viruses for retroviruses","volume":"1407","author":"Solomon","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"issue":"6","key":"10.1016\/j.virol.2026.111025_bib48","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1128\/JVI.72.6.4694-4703.1998","article-title":"CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization","volume":"72","author":"Sullivan","year":"1998","journal-title":"J. Virol."},{"issue":"7572","key":"10.1016\/j.virol.2026.111025_bib49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nature15400","article-title":"SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by nef","volume":"526","author":"Usami","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.virol.2026.111025_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128562","article-title":"Immunogens modeling a fusion-intermediate conformation of gp41 elicit antibodies to the membrane proximal external region of the HIV envelope glycoprotein","volume":"10","author":"Vassell","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2026.111025_bib51","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3389\/fimmu.2017.00580","article-title":"Pathophysiology of CD4+ T-Cell depletion in HIV-1 and HIV-2 infections","volume":"8","author":"Vidya Vijayan","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.virol.2026.111025_bib52","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2026.111025_bib53","first-page":"239","article-title":"The discovery of the CCR5 receptor antagonist, UK-427,857, A new agent for the treatment of HIV infection and AIDS","volume":"vol. 43","author":"Wood","year":"2005"},{"issue":"1","key":"10.1016\/j.virol.2026.111025_bib54","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0042-6822(03)00521-X","article-title":"Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains","volume":"315","author":"Xiang","year":"2003","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.virol.2026.111025_bib55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.celrep.2015.08.055","article-title":"IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein","volume":"13","author":"Yu","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.virol.2026.111025_bib56","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111400119","article-title":"SARS-CoV-2 spreads through cell-to-cell transmission","volume":"119","author":"Zeng","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2026.111025_bib57","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.coviro.2014.04.001","article-title":"Structures of viral membrane proteins by high-resolution cryoEM","volume":"5","author":"Zhou","year":"2014","journal-title":"Curr. Opin. Virol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226002400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682226002400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:05:15Z","timestamp":1788192315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682226002400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"alternative-id":["S0042682226002400"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2026.111025","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a virus particle fusion assay to study and target virus entry","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2026.111025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111025"}}